Amundi Asset Management US’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Amundi Asset Management US’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	$18.7M	Sell	109,345 -16,513	-13%	-$3.27M	0.01%	688
2020 Q4	$27.6M	Sell	125,858 -168,112	-57%	-$36.3M	0.02%	548
2020 Q3	$48.8M	Sell	293,970 -70,629	-19%	-$9.66M	0.05%	334
2020 Q2	$41.6M	Buy	364,599 +54,559	+18%	+$5.29M	0.05%	349
2020 Q1	$23.8M	Buy	310,040 +75,877	+32%	+$6.8M	0.04%	367
2019 Q4	$30.2M	Buy	+234,163	New	+$22.6M	0.04%	439
2019 Q1	–	Sell	-268,100	Closed	-$11.4K	–	1696
2018 Q4	$11.4K	Buy	268,100 +82,900	+45%	+$3.3M	0.01%	621
2018 Q3	$8.72M	Buy	+185,200	New	+$10.3M	0.01%	773

Other funds holding MRTX

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Amundi Asset Management US's MRTX Position: Q1 2021 in Review

Amundi Asset Management US reduced its Mirati Therapeutics, Inc. Common Stock (MRTX) stake by 13% in Q1 2021, selling an estimated $3.27M and leaving 109,345 shares worth $18.7M. The position accounts for 0.01% of the portfolio, ranked #688.

Amundi Asset Management US first reported a position in MRTX in Q3 2018 and has held it in 8 quarters since. The position peaked at $48.8M in Q3 2020. 260 funds tracked by Wall St. Rank hold MRTX as of Q1 2021.

Amundi Asset Management US held 109,345 shares of Mirati Therapeutics, Inc. Common Stock worth $18.7M as of Q1 2021.
Amundi Asset Management US sold 16,513 Mirati Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $3.27M.
Mirati Therapeutics, Inc. Common Stock made up 0.01% of Amundi Asset Management US's portfolio in Q1 2021, its #688 holding.
Amundi Asset Management US first reported a position in Mirati Therapeutics, Inc. Common Stock in Q3 2018 and has held it in 8 quarters since.
Amundi Asset Management US's Mirati Therapeutics, Inc. Common Stock position peaked at $48.8M in Q3 2020.
260 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Amundi Asset Management US's 13F filing for Q1 2021, filed 17 May 2021.